Rick Flath
President
Institute for Life Sciences Collaboration
Connecticut, New York City, and Los Angeles
www.ilscollaboration.org

The Institute for Life Sciences Collaboration's Mission:


At the Institute for Life Sciences Collaboration (ILSC) (a 501(c)3 organization), we believe that collaboration and innovation are the best ways to tackle the world's most pressing health challenges. As a result, we strive to encourage and enhance the development of innovative initiatives and collaborative approaches. To achieve our mission, we have formed strong partnerships with leading experts, academic institutions, organizations, and key stakeholders, including United Nations Association of the USA (UNA-USA) and other NGOs. Through our collaborations, we aim to make meaningful and measurable improvements in the global healthcare landscape and civil society.

Today's Topic:

Funding and Focus for R&D and Applications – Public and Private

Non-Profit Funding: Donations





National Institute of Health

Invests approximately \$32-35B over the last several years:

- Awards go to 50,000 competitive grants
- 300,000 Researchers
- 2500 Universities, etc.

Schools that routinely receive over \$100M

- Johns Hopkins 347M
- Harvard (all) 160M
- New York University 100M
- Columbia 185M
- Ohio State 100M
- Stanford 235M
- University of North Carolina, Chapel Hil 194M
- University of Alabama 125M
- UCLA 180M
- UCSD 225M
- UCSF 245M
- University of Pennsylvania 248M
- University of Pittsburgh 255M
- University of Washington 208M
- Vanderbilt 107M
- Washington University 219M
- Yale University 214M

Investing in BioTech

- S&P BioTech Index has declined 50% from its peak in July 2015
- Currently down 25% from peak

Some reasons for the downturn:

- Call for tighter drug pricing controls
- Unclear direction of healthcare law
- Unclear pricing policies for pharmaceuticals
- Tax policy (overseas money)
- Terrible "brand" identification in the public eye

All lead to better opportunities for investors

Where does Pharma place in the Fortune 500?

- Johnson & Johnson ranks 35th revenues of \$72B profit of \$16.5B
- Pfizer ranks 54th revenues of \$53B profit of \$7.2B
- Merck ranks 69th revenues of \$40B profit of \$3.9B

Comparison: Healthcare/Pharmacies

- CVS ranks 7th revenues \$177B profit \$5.3B
- Express Scripts ranks 22nd revenues \$100 B profit \$3.4B

Venture Capital Investments First Quarter 2017:


• Top: Internet - \$5.8B

• Healthcare - \$3.7B

In the next five years, the "hot investments" will be Artificial Intelligence and Machine Learning

How to prepare for a pitch

From Canaan Partners, Entrepreneur Pitchbook



Thank you!

Rick Flath